<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="131305">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02137577</url>
  </required_header>
  <id_info>
    <org_study_id>acotec-03</org_study_id>
    <nct_id>NCT02137577</nct_id>
  </id_info>
  <brief_title>Effectiveness and Safety Study of Drug Eluting Balloon(DEB) in Percutaneous Transluminal Angioplasty(PTA) Procedure of the Infrapopliteal Artery</brief_title>
  <official_title>Prospective, Multi-center and Randomized Controlled Clinical Study to Verify Effectiveness and Safety of Drug-eluting Balloon in PTA Procedure of the Infrapopliteal Artery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Acotec Scientific Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Acotec Scientific Co., Ltd</source>
  <oversight_info>
    <authority>China: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether DEB is more effective than common PTA
      balloon using under  in long-term vessel patency and inhibiting restenosis in the
      infrapopliteal artery.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">November 2016</completion_date>
  <primary_completion_date type="Anticipated">August 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change from baseline Restenosis rate of target vessel at 6 months, 12months, 18months, 24months</measure>
    <time_frame>6 months, 12 months, 18 months, 24months</time_frame>
    <safety_issue>No</safety_issue>
    <description>stenosis over 50% is defined as restenosis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>device success rate</measure>
    <time_frame>during the operation(after using the DEB catheter)</time_frame>
    <safety_issue>No</safety_issue>
    <description>DEB catheter can reach the target lesions,  expand as expected(not broken), and  withdraw successfully.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>technical success rates</measure>
    <time_frame>during the operation(after using the DEB catheter)</time_frame>
    <safety_issue>No</safety_issue>
    <description>The blood supply of the target lesion recovered after treatment, and residual stenosis  less than 50%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>operation success rate</measure>
    <time_frame>during the operation(after using the DEB catheter)</time_frame>
    <safety_issue>No</safety_issue>
    <description>both device succeed and technical succeed, and without clinical complication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>if occured clinically driven TLR( target lesion revascularization) at 6 months, 12 months, 18 months, 24 months</measure>
    <time_frame>6 months, 12 months, 18 months, 24 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Clinically driven TLR is defined as revascularization performed on a patient who returns with clinical symptoms such as: resting pain occur again, ulcer deterioration, new foot ulcers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>if occured major amputation at 6 months, 12 months, 18 months, 24 months</measure>
    <time_frame>6 months, 12 months, 18 months, 24 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>major amputation at the index limb(major amputation is defined as an amputation above the foot)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ulcer healing rate</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline ABI(ankle brachial index) at 6 months, 12 months, 18 months, 24 months</measure>
    <time_frame>6 months, 12 months, 18 months, 24 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>measure ankle brachial index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change from baseline Rutherford stage at 6 months, 12 months, 18 months, 24 months</measure>
    <time_frame>6 months, 12 months, 18 months, 24 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>based the following definition of Rutherford stage, evaluate the stage of patient. Then compare the stage of patient just after procedure and 6 months after treatment
Stage clinical symptom
0 asymptomatic
mild claudication
moderate claudication
severe claudication
ischemic rest pain
minor tissue loss
ulceration or gangrene</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Peripheral Artery Disease</condition>
  <arm_group>
    <arm_group_label>drug eluting balloon catheter</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>use drug eluting balloon catheter to inflate the stenosis or occlusion in below popliteal artery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>common balloon catheter(uncoated drug)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>use common balloon catheter to inflate stenosis or occlusion in below  popliteal artery</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>drug eluting balloon catheter (trade name: Lotus/Tulip)</intervention_name>
    <description>drug eluting dilation catheter</description>
    <arm_group_label>drug eluting balloon catheter</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>common percutaneous transluminal angioplasty balloon catheter (trade name: Amphirion DEEP)</intervention_name>
    <description>common PTA catheter</description>
    <arm_group_label>common balloon catheter(uncoated drug)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age between 18 and 85 years

          -  Patients with peripheral artery disease (PAD), with Rutherford classification between
             4 and 6

          -  an occlusion or a minimum grade of stenosis Primary over 70% in the below popliteal
             artery

          -  The expected survival time is more than 1 year

          -  signed Patient informed consent form

        Exclusion Criteria:

          -  Serum creatinine clearance rate less than 30ml/min in patients

          -  patients with acute thrombosis requiring lysis or thrombectomy

          -  patient with a lysis or an lower limb intervention as a therapy within the last 6
             weeks

          -  patient requiring intervention in both lower limbs at the same time

          -  In-stent restenosis in the blow-knee popliteal artery

          -  target lesion can't be cross by the guide wire

          -  the stenosis rate of proximal outflow more than 30% with or without intervention

          -  the length of the stenosis or occlusion in proximal outflow(including the Iliac
             artery, the superficial femoral artery, the Popliteal artery) more than 150mm before
             intervention

          -  stenosis or occlusion of distal outflow for below-the-ankle artery.

          -  expected major amputations at the index limb before intervention

          -  known hypersensitivity to aspirin, heparin, clopidogrel,paclitaxel, contrast medium,
             etc.

          -  patients participating in another clinical trials with interfere with this trial in
             the same time

          -  pregnancy and lactating woman

          -  untreatable bleeding diatheses
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>People's Liberation Army General Hospital</name>
      <address>
        <city>BeiJing</city>
        <zip>100853</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wei Guo</last_name>
      <phone>+10 86 66936336</phone>
      <email>hindley007@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>May 12, 2014</lastchanged_date>
  <firstreceived_date>May 5, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>drug eluting balloon catheter</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
